Clinical trialNCT00515827CompletedPhase 2Interventional

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment53HIV Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs. The purpose of this study is to assess the effectiveness of raltegravir in further reducing viral load in HIV infected patients that have already achieved viral suppression below the level of detection of standard viral load assays when added to antiretroviral therapy (ART).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John W Mellors, MD
University of Pittsburgh Medical Center
Study Chair
clinicaltrials.gov ↗
Joseph J Eron Jr., MD
University of North Carolina, Chapel Hill
Study ChairKOL profile →
clinicaltrials.gov ↗
Rajesh T Gandhi, MD
Massachusetts General Hospital
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alabama Therapeutics Crs
Birmingham, Alabama, United States
Stanford Crs
Palo Alto, California, United States
Ucsf Aids Crs
San Francisco, California, United States
Harbor-Ucla Med. Ctr. Crs
Torrance, California, United States
University of Colorado Hospital Crs
Aurora, Colorado, United States
Northwestern University Crs
Chicago, Illinois, United States
Beth Israel Deaconess Med. Ctr., Actg Crs
Boston, Massachusetts, United States
Massachusetts General Hospital Actg Crs
Boston, Massachusetts, United States
Washington U Crs
St Louis, Missouri, United States
Columbia P&s Crs
New York, New York, United States
Cornell Crs
New York, New York, United States
Harlem Actg Crs
New York, New York, United States
Ny Univ. Hiv/aids Crs
New York, New York, United States
Univ. of Rochester Actg Crs
Rochester, New York, United States
Unc Aids Crs
Chapel Hill, North Carolina, United States
Duke Univ. Med. Ctr. Adult Crs
Durham, North Carolina, United States
Metrohealth Crs
Cleveland, Ohio, United States
Hosp. of the Univ. of Pennsylvania Crs
Philadelphia, Pennsylvania, United States
Pitt Crs
Pittsburgh, Pennsylvania, United States
University of Washington Aids Crs
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRaltegravir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2007
Primary completion: 30 Sept 2008
Completion: 30 Nov 2008
Last update posted: 4 Nov 2021
Registered enrollment: 53
Registry id: NCT00515827

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.